ClinicalTrials.gg
CompletedNCT02020577Updated Jun 22, 2017Results posted

Trial of Afatinib (BIBW 2992) + Cetuximab in Advanced Solid Tumours

A Phase 1 interventional study of Cetuximab( erbitux®) and Afatinib in Neoplasms, sponsored by Boehringer Ingelheim. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-06-22.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
58
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The trial is divided in two parts, Part A and Part B. Part A will involve dose-finding of dose-limiting toxicity (DLT) and MTD in patients with advanced solid tumours. Part B will involve expansion of the MTD to 3 cohorts including non-small cell lung cancer squamous histology, recurrent/ metastatic squamous cell carcinoma of head and neck and other advanced solid tumours (except sarcomas).

02

Conditions studied

  • Neoplasms

Browse trials for

03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,325 are open to participants now.

This study's enrollment of 58 is close to the median of 60 across 7,706 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Part A only

  1. Patients must have advanced malignant solid tumours that are or unresectable
  2. At least one measurable or evaluable (non-measurable) lesion per 1.1 Part B only
  3. Patients must have:

    1. per RECIST 1.1
    2. diagnosis of one of the following

      • Advanced Non-Small Cell Lung Cancer -Squamous Histology (NSCLC-SQ) with no more than 2 for advanced/metastatic disease ( prior EGFR directed treatment is permitted) or
      • Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck (R/M SCCHN) no more than 2 lines of chemotherapy for advanced disease and no more than 1 line of prior cetuximab permitted.

    or

    • Other malignant solid tumours except sarcomas (for metastatic colorectal cancer, only wild type KRAS are permitted) Part A and B
  4. Age 18 years or older
  5. Written that is consistent with ICH-GCP guidelines and local law.
  6. Histological/Cytological confirmed diagnosis of malignant solid tumours (exclusion of sarcomas)
  7. Advanced disease for whom standard treatment is ineffective or no longer effective
  8. Recovered from previous therapy related AE to \</= Grade 1 at the study entry (except, for stable sensory neuropathy \</= Grade 2 and alopecia)
  9. (ECOG) performance score 0 or 1.
  10. Adequate organ function as defined by the following criteria:

    • >50% or within institutional values
    • (ANC) >1500/ mm3
    • count >75.000/ mm3
    • Estimated > 45ml/ min
    • Total \<1.5 times upper limit of institutional normal
    • Aspartate amino transferase () or alanine amino transferase (ALT) \<3 x upper limit of institutional normal () (if related to liver metastases\< 5xULN)

Exclusion criteria

Exclusion criteria:

  1. Chemotherapy, biological therapy or agents within 4 weeks prior to the start of study treatment.
  2. Hormonal anti-cancer treatment within 2 weeks prior to the start of study treatment (continued use of anti-androgens and/or gonadorelin analogues [LHRH] is permitted)
  3. Radiotherapy within 4 weeks prior to the start of study treatment, except as follows:

    1. Palliative radiation to target organs other than chest may be allowed up to 2 weeks prior to study treatment, and
    2. Single dose palliative treatment for symptomatic outside above allowance to be discussed with sponsor prior to enrolling.
  4. Major surgery (as judged by the investigator) within 4 weeks before starting study treatment or scheduled for surgery during the projected course of the study
  5. Known to afatinib or the of any of the trial drugs
  6. History or presence of cardiovascular abnormalities such as uncontrolled hypertension, congestive heart failure classification of 3, unstable angina or poorly controlled arrhythmia as determined by the investigator. Myocardial infarction within 6 months prior start treatment.
  7. Female patients of who:

    1. are nursing or
    2. are pregnant or
    3. are not using an acceptable method of or do not plan to continue using this method throughout the study and/or do not agree to submit to pregnancy testing required by this protocol.
  8. Any history of or concomitant condition that, in the opinion of the Investigator, would compromise the patient's ability to comply with the study or interfere with the evaluation of the efficacy and safety of the test drug
  9. Previous or concomitant at other sites, except effectively treated non-melanoma skin cancers, carcinoma in situ of the cervix, ductal carcinoma in situ or effectively treated malignancy that has been in remission for more than 3 years and is considered to be cured.
  10. Requiring treatment with any of the prohibited concomitant medications listed in the protocol that can not be stopped for the duration of trial participation
  11. Known pre-existing interstitial lung disease
  12. Any history or presence of poorly controlled gastrointestinal disorders that could affect the absorption of the study drug (e.g. Crohn's disease, ulcerative colitis, chronic diarrhea, malabsorption)
  13. Active infection (defined as presence of HepB sAg and/ or Hep B DNA), active infection (defined as presence of Hep C RNA) and/or known carrier.
  14. Prior participation in an afatinib clinical study, even if not assigned to afatinib treatment.
  15. Meningeal carcinomatosis
  16. Patients with brain or subdural metastases are not eligible, unless they have completed local therapy and have discontinued the use of or have been on stable dose of corticosteroids for at least 4 weeks before starting study treatment. Any symptoms attributed to must be stable for at least 4 weeks before starting study treatment.
  17. Any SPC listed for cetuximab
  18. Use of alcohol or drugs incompatible with patient participation in the study in the investigator's opinion.
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
58 participants (actual)

Study arms

  • Experimental
    combination arm

    Patients to receive afatinib once daily plus weekly cetuximab infusion

    Drug: Cetuximab( erbitux®) · Drug: Afatinib

Interventions

06

What researchers measure

Primary outcomes

  1. MTD of Afatinib in Combination With Cetuximab Based on the Number of Patients With DLTs During the First Treatment Cycle (Afatinib).

    Maximum Tolerated Dose (MTD) of Afatinib in combination with cetuximab based on the number of patients with dose limiting toxicity (DLT) during the first treatment cycle (Dose escalation part). The MTD is defined as the highest dose level at which less than 33% of the patients experience DLT in first treatment cycle.

    Time frame: First 21 days treatment cycle

  2. Dose Limiting Toxicities During Cycle 1

    Number of Patients With Dose Limiting Toxicity (DLT) Occurring during Cycle 1. The following drug related AEs qualified as DLT: 1) CTCAE Grade ≥2 decrease in cardiac left ventricular function 2) CTCAE Grade 2 diarrhoea lasting for ≥7 days, despite appropriate use of standard antidiarrheal therapy based on Protocol Amendment 1 dated 22 Oct 2013 3) CTCAE Grade ≥3 diarrhoea despite appropriate use of standard anti-diarrheal therapy for at least 2 days. 4) CTCAE Grade ≥3 nausea and/or vomiting despite appropriate use of standard anti-emetics for at least 3 days 5) CTCAE Grade ≥3 rash despite standard medical management. 6) CTCAE Grade ≥3 fatigue lasting more than 7 days. 7) All other AEs of CTCAE Grade ≥3 (except alopecia and allergic reaction) that led to an interruption of afatinib and/or cetuximab dosing for more than 14 days until recovery to baseline or Grade 1, whichever was higher. 8) CTCAE Grade 4 hypomagnesemia or Grade 3 hypomagnesemia with clinically-significant sequelae

    Time frame: First 21-day treatment cycle

  3. MTD of Afatinib in Combination With Cetuximab Based on the Number of Patients With DLTs During the First Treatment Cycle (Cetuximab).

    Maximum Tolerated Dose (MTD) of Afatinib in combination with cetuximab based on the number of patients with DLTs during the first treatment cycle (Dose escalation part).

    Time frame: First treatment cycle

Secondary outcomes

  1. Dose Limiting Toxicities During All Treatment Cycles

    Number of patients with DLT occuring during all treatment cycle is presented

    Time frame: All treatment cycle (each treatment cycle of 21 days)

  2. Recommended Phase II Dose Based on the Number of Patients With Dose Limiting Toxicity Events (Cetuximab)

    MTD was deemed the recommended Phase II dose based on the number of patients with dose limiting toxicity events at all treatment cycles.

    Time frame: All treatment cycle (each treatment cycle of 21 days)

  3. Best Overall Response

    Best overall response (according to RECIST version 1.1) was defined as the best response recorded at any time from the first administration of afatinib or cetuximab to the End of Treatment (EOT). As Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; progression, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression.

    Time frame: Post baseline tumour-imaging was performed at every 6 weeks (in the week preceding the start of Cycles 3, 5, 7, 9, 11, etc.) until EOT; up to 19 months

  4. Objective Response

    Objective response was defined as the proportion of patients with measurable disease having at least a best overall response of complete response (CR) or partial response (PR), according to RECIST version 1.1. As Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; progression, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression.

    Time frame: Post baseline tumour-imaging was performed at every 6 weeks (in the week preceding the start of Cycles 3, 5, 7, 9, 11, etc.) until EOT; up to 19 months

  5. Disease Control Rate

    For patients with measurable disease, disease control was defined as the proportion of patients having at least a best overall response of CR, PR or stable disease (SD). As Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; progression, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression

    Time frame: Post baseline tumour-imaging was performed at every 6 weeks (in the week preceding the start of Cycles 3, 5, 7, 9, 11, etc.) until EOT; up to 19 months

  6. Recommended Phase II Dose Based on the Number of Patients With Dose Limiting Toxicity Events (Afatinib)

    MTD was deemed the recommended Phase II dose based on the number of patients with dose limiting toxicity events at all treatment cycles.

    Time frame: All treatment cycle (each treatment cycle of 21 days)

07

Results

Posted Feb 12, 2016

Participant flow

Participant flow — Overall Study
MilestoneAfatinib 30mg+Cetuximab 250 mg/m²Afatinib 40mg+Cetuximab 250 mg/m²
Started355
Completed00
Not completed355
Withdrew: Progressive disease338
Withdrew: Other ae or clinical progression015
Withdrew: Withdrawal by subject01
Withdrew: Other than stated above01

Outcome measures

PrimaryMTD of Afatinib in Combination With Cetuximab Based on the Number of Patients With DLTs During the First Treatment Cycle (Afatinib).

Maximum Tolerated Dose (MTD) of Afatinib in combination with cetuximab based on the number of patients with dose limiting toxicity (DLT) during the first treatment cycle (Dose escalation part). The MTD is defined as the highest dose level at which less than 33% of the patients experience DLT in first treatment cycle.

Time frame:
First 21 days treatment cycle
Reported as:
Number · mg
MTD of Afatinib in Combination With Cetuximab Based on the Number of Patients With DLTs During the First Treatment Cycle (Afatinib).
mgAfatinib 30mg+Cetuximab 250 mg/m²Afatinib 40mg+Cetuximab 250 mg/m²
MTD of Afatinib in Combination With Cetuximab Based on the Number of Patients With DLTs During the First Treatment Cycle (Afatinib).NA40
PrimaryDose Limiting Toxicities During Cycle 1

Number of Patients With Dose Limiting Toxicity (DLT) Occurring during Cycle 1. The following drug related AEs qualified as DLT: 1) CTCAE Grade ≥2 decrease in cardiac left ventricular function 2) CTCAE Grade 2 diarrhoea lasting for ≥7 days, despite appropriate use of standard antidiarrheal therapy based on Protocol Amendment 1 dated 22 Oct 2013 3) CTCAE Grade ≥3 diarrhoea despite appropriate use of standard anti-diarrheal therapy for at least 2 days. 4) CTCAE Grade ≥3 nausea and/or vomiting despite appropriate use of standard anti-emetics for at least 3 days 5) CTCAE Grade ≥3 rash despite standard medical management. 6) CTCAE Grade ≥3 fatigue lasting more than 7 days. 7) All other AEs of CTCAE Grade ≥3 (except alopecia and allergic reaction) that led to an interruption of afatinib and/or cetuximab dosing for more than 14 days until recovery to baseline or Grade 1, whichever was higher. 8) CTCAE Grade 4 hypomagnesemia or Grade 3 hypomagnesemia with clinically-significant sequelae

Time frame:
First 21-day treatment cycle
Reported as:
Number · Participants
Dose Limiting Toxicities During Cycle 1
ParticipantsAfatinib 30mg+Cetuximab 250 mg/m²Afatinib 40mg+Cetuximab 250 mg/m²
Dose Limiting Toxicities During Cycle 100
PrimaryMTD of Afatinib in Combination With Cetuximab Based on the Number of Patients With DLTs During the First Treatment Cycle (Cetuximab).

Maximum Tolerated Dose (MTD) of Afatinib in combination with cetuximab based on the number of patients with DLTs during the first treatment cycle (Dose escalation part).

Time frame:
First treatment cycle
Reported as:
Number · mg/m2
MTD of Afatinib in Combination With Cetuximab Based on the Number of Patients With DLTs During the First Treatment Cycle (Cetuximab).
mg/m2Afatinib 30mg+Cetuximab 250 mg/m²Afatinib 40mg+Cetuximab 250 mg/m²
MTD of Afatinib in Combination With Cetuximab Based on the Number of Patients With DLTs During the First Treatment Cycle (Cetuximab).NA250
SecondaryDose Limiting Toxicities During All Treatment Cycles

Number of patients with DLT occuring during all treatment cycle is presented

Time frame:
All treatment cycle (each treatment cycle of 21 days)
Reported as:
Number · Participants
Dose Limiting Toxicities During All Treatment Cycles
ParticipantsAfatinib 30mg+Cetuximab 250 mg/m²Afatinib 40mg+Cetuximab 250 mg/m²All Patients
Dose Limiting Toxicities During All Treatment Cycles099
SecondaryRecommended Phase II Dose Based on the Number of Patients With Dose Limiting Toxicity Events (Cetuximab)

MTD was deemed the recommended Phase II dose based on the number of patients with dose limiting toxicity events at all treatment cycles.

Time frame:
All treatment cycle (each treatment cycle of 21 days)
Reported as:
Number · mg/m2
Recommended Phase II Dose Based on the Number of Patients With Dose Limiting Toxicity Events (Cetuximab)
mg/m2Afatinib 30mg+Cetuximab 250 mg/m²Afatinib 40mg+Cetuximab 250 mg/m²
Recommended Phase II Dose Based on the Number of Patients With Dose Limiting Toxicity Events (Cetuximab)NA250
SecondaryBest Overall Response

Best overall response (according to RECIST version 1.1) was defined as the best response recorded at any time from the first administration of afatinib or cetuximab to the End of Treatment (EOT). As Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; progression, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression.

Time frame:
Post baseline tumour-imaging was performed at every 6 weeks (in the week preceding the start of Cycles 3, 5, 7, 9, 11, etc.) until EOT; up to 19 months
Reported as:
Number · Percentage of participants
Best Overall Response
Percentage of participantsAfatinib 30mg+Cetuximab 250 mg/m²Afatinib 40mg+Cetuximab 250 mg/m²All Patients
Complete Response (CR)0.00.00.0
Partial Response (PR)0.00.00.0
Stable Disease (SD)66.752.753.4
Progressive disease (PD)33.334.534.5
Not evaluable (NE)/Missing0.012.712.1
SecondaryObjective Response

Objective response was defined as the proportion of patients with measurable disease having at least a best overall response of complete response (CR) or partial response (PR), according to RECIST version 1.1. As Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; progression, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression.

Time frame:
Post baseline tumour-imaging was performed at every 6 weeks (in the week preceding the start of Cycles 3, 5, 7, 9, 11, etc.) until EOT; up to 19 months
Reported as:
Number · Percentage of participants
Objective Response
Percentage of participantsAfatinib 30mg+Cetuximab 250 mg/m²Afatinib 40mg+Cetuximab 250 mg/m²All Patients
Objective Response0.00.00.0
SecondaryDisease Control Rate

For patients with measurable disease, disease control was defined as the proportion of patients having at least a best overall response of CR, PR or stable disease (SD). As Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; progression, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression

Time frame:
Post baseline tumour-imaging was performed at every 6 weeks (in the week preceding the start of Cycles 3, 5, 7, 9, 11, etc.) until EOT; up to 19 months
Reported as:
Number · Percentage of participants
Disease Control Rate
Percentage of participantsAfatinib 30mg+Cetuximab 250 mg/m²Afatinib 40mg+Cetuximab 250 mg/m²All Patients
Disease Control Rate66.752.753.4
SecondaryRecommended Phase II Dose Based on the Number of Patients With Dose Limiting Toxicity Events (Afatinib)

MTD was deemed the recommended Phase II dose based on the number of patients with dose limiting toxicity events at all treatment cycles.

Time frame:
All treatment cycle (each treatment cycle of 21 days)
Reported as:
Number · mg
Recommended Phase II Dose Based on the Number of Patients With Dose Limiting Toxicity Events (Afatinib)
mgAfatinib 30mg+Cetuximab 250 mg/m²Afatinib 40mg+Cetuximab 250 mg/m²
Recommended Phase II Dose Based on the Number of Patients With Dose Limiting Toxicity Events (Afatinib)NA40

Adverse events

Collected over From first drug administration until 28 days after last drug administration, up to 19 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Afatinib 30mg+Cetuximab 250 mg/m²—1/3 (33.3%)3/3 (100%)
Afatinib 40mg+Cetuximab 250 mg/m²—31/55 (56.4%)54/55 (98.2%)
All Patients—32/58 (55.2%)57/58 (98.3%)
Most frequent serious events
Showing 10 of 47
Most frequent serious events
EventAfatinib 30mg+Cetuximab 250 mg/m²Afatinib 40mg+Cetuximab 250 mg/m²All Patients
Upper limb fractureInjury, poisoning and procedural complications1/30/551/58
Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/35/556/58
Cognitive disorderNervous system disorders1/30/551/58
SepsisInfections and infestations0/33/553/58
DehydrationMetabolism and nutrition disorders0/33/553/58
DiarrhoeaGastrointestinal disorders0/32/552/58
AstheniaGeneral disorders0/32/552/58
Respiratory tract infectionInfections and infestations0/32/552/58
HypercalcaemiaMetabolism and nutrition disorders0/32/552/58
HypokalaemiaMetabolism and nutrition disorders0/32/552/58
Most frequent other events
Showing 10 of 55
Most frequent other events
EventAfatinib 30mg+Cetuximab 250 mg/m²Afatinib 40mg+Cetuximab 250 mg/m²All Patients
Dermatitis acneiformSkin and subcutaneous tissue disorders2/322/5524/58
Dry skinSkin and subcutaneous tissue disorders2/314/5516/58
DiarrhoeaGastrointestinal disorders1/335/5536/58
HypomagnesaemiaMetabolism and nutrition disorders0/326/5526/58
ConstipationGastrointestinal disorders1/36/557/58
StomatitisGastrointestinal disorders1/311/5512/58
FatigueGeneral disorders1/311/5512/58
ConjunctivitisInfections and infestations1/35/556/58
ParonychiaInfections and infestations1/317/5518/58
ArthralgiaMusculoskeletal and connective tissue disorders1/30/551/58

Baseline characteristics

Treated set: This patient set includes all patients enrolled in the trial who were documented to have taken at least one dose of study medication.

Age, Continuous
Age, Continuous(Years)Afatinib 30mg+Cetuximab 250 mg/m²Afatinib 40mg+Cetuximab 250 mg/m²Total
Mean63.3 ± 7.661.0 ± 11.461.1 ± 11.2
Sex: Female, Male
Sex: Female, Male(Participants)Afatinib 30mg+Cetuximab 250 mg/m²Afatinib 40mg+Cetuximab 250 mg/m²Total
Female02020
Male33538
08

Study locations

2 sites
  • 1200.122.33001 Boehringer Ingelheim Investigational Site
    Villejuif Cedex, France
  • 1200.122.34001 Boehringer Ingelheim Investigational Site
    Madrid, Spain
09

References and documents

Publications

  • Gazzah A, Boni V, Soria JC, Calles A, Even C, Doger B, Mahjoubi L, Bahleda R, Ould-Kaci M, Esler A, Nazabadioko S, Calvo E. A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours. Eur J Cancer. 2018 Nov;104:1-8. doi: 10.1016/j.ejca.2018.07.011. Epub 2018 Oct 1. Erratum In: Eur J Cancer. 2019 Sep;119:198. doi: 10.1016/j.ejca.2018.12.018. PubMed 30278378 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2013, a primary completion of Jan 2015 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2016, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2013
First posted
Dec 25, 2013
Start
Dec 2013
Primary completionActual
Jan 2015
CompletionActual
Apr 2016
Results first posted
Feb 12, 2016
Last update
Jun 22, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02020577
Responsible party
Sponsor
First posted
Dec 25, 2013
Start date
Dec 2013
Primary completion
Jan 2015
Completion
Apr 2016
Results posted
Feb 12, 2016
Last update
Jun 22, 2017

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cetuximab · Afatinib

Start the discussion